Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tarsus Pharmaceuticals's quarterly market cap
declined
from Dec. 2025 ($3,484.3 Mil) to Mar. 2026 ($3,017.9 Mil) and
declined
from Mar. 2026 ($3,017.9 Mil) to Jun. 2026 ($2,731.2 Mil).
Tarsus Pharmaceuticals's annual market cap
increased
from Dec. 2023 ($692.8 Mil) to Dec. 2024 ($2,123.4 Mil) and
increased
from Dec. 2024 ($2,123.4 Mil) to Dec. 2025 ($3,484.3 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Tarsus Pharmaceuticals's Enterprise Value for Today is $2,467.6 Mil.
Tarsus Pharmaceuticals (NAS:TARS) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Tarsus Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tarsus Pharmaceuticals Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tarsus Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where Tarsus Pharmaceuticals's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Tarsus Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tarsus Pharmaceuticals (TARS) has a Market Cap of $2,844.5 Mil as of Aug. 09, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Tarsus Pharmaceuticals and its competitors. According to the industry distribution chart, Tarsus Pharmaceuticals ranks #130 out of 1420 companies in the Biotechnology industry, placing it in the top 9.2%.
Is Tarsus Pharmaceuticals' Market Cap too high?
Tarsus Pharmaceuticals' current Market Cap is $2,844.5 Mil. The Biotechnology industry median Market Cap is 116.96. Tarsus Pharmaceuticals' value of $2,844.5 Mil is 2332.1% above this industry median. Based on the distribution chart, Tarsus Pharmaceuticals ranks #130 out of 1420 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Tarsus Pharmaceuticals has a GF Score™ of 46/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tarsus Pharmaceuticals' Market Cap compare to VERA and BEAM?
According to the Biotechnology industry distribution chart, Tarsus Pharmaceuticals ranks #130 out of 1420 companies for Market Cap. This places Tarsus Pharmaceuticals in the top 9% of its industry — outperforming the majority of peers. The industry median Market Cap is 116.96. Tarsus Pharmaceuticals' value of $2,844.5 Mil is 2332.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 116.96, based on 1,420 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tarsus Pharmaceuticals's current Market Cap of $2,844.5 Mil is 2332.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Tarsus Pharmaceuticals and its competitors. For the Biotechnology industry, the median Market Cap is 116.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tarsus Pharmaceuticals's current Market Cap is $2,844.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tarsus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Tarsus Pharmaceuticals (TARS) is currently considered Significantly Undervalued. The stock's GF Value™ is $160.53, compared to a current price of $64.82 — trading 59.6% below its estimated fair value. The current Market Cap is $2,844.5 Mil and 2332.1% above the Biotechnology industry median of 116.96. Tarsus Pharmaceuticals' overall GF Score™ is 46/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Tarsus Pharmaceuticals (TARS), the current Market Cap is $2,844.5 Mil as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tarsus Pharmaceuticals (TARS) Overvalued in 2026?
Based on GuruFocus' analysis, Tarsus Pharmaceuticals stock appears to be undervalued.
The current stock price of $64.82 is trading 59.6% below its estimated GF Value™ of $160.53.
GuruFocus considers Tarsus Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for TARS:
Market Cap: $2,844.5 Mil
GF Value™: $160.53 vs. price of $64.82 (59.6% below fair value)
Industry Position: 2332.1% above the Biotechnology median (#130 of 1420)
No single metric tells the full story. See the TARS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
46GF Score
Get the complete analysis for TARS
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TARS has been successfully added to your 
